ABK Biomedical
ABK Biomedical is a clinical-stage medical device company developing proprietary glass-based Y-90 radioembolization microspheres (Eye90) and embolic microspheres (Easi-Vue) for interventional oncology treatment of liver cancer patients.
- Company typePrivate
- Founded2012
- HeadquartersHalifax, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ABK Biomedical does
ABK Biomedical is a clinical-stage medical device company headquartered in Halifax, Nova Scotia, founded in 2012 as a spin-out from Dalhousie University by Daniel Boyd and Sharon Kehoe. The company develops proprietary glass-based embolic and radioembolic microspheres for interventional oncology, with two core products: Eye90 microspheres, an investigational Yttrium-90 (Y-90) radioembolization therapy for liver cancer (notably hepatocellular carcinoma) currently advancing through the Route90 pivotal Phase III FDA IDE trial; and Easi-Vue embolic microspheres, which holds FDA 510(k) clearance. Eye90 incorporates a differentiated dual-syringe delivery system and is supported by an FDA Breakthrough Device Designation granted in 2023, positioning the product for an accelerated PMA pathway.
The company is pre-commercial on its lead asset. Its business model centers on eventual direct sale of single-use microsphere devices and配套 delivery systems to hospital-based interventional radiology and oncology departments, supplemented by long-term isotope supply partnerships. To secure commercial readiness, ABK has formalized a long-term Y-90 supply agreement with the University of Missouri Research Reactor (MURR)—the sole U.S. producer of Yttrium-90—and is constructing a GMP manufacturing facility in Ashland, Missouri with COR Development, alongside building a U.S. field sales presence. The company is ISO 13485 certified and operates with 11–50 employees, led by CEO Michael Mangano, CMO Aravind Arepally, M.D., and CCO Gary Donofrio.
ABK has raised approximately $140M CAD (over $100M USD) across multiple rounds, including a $30M Series C (Dec 2022, Santé Ventures lead) and a $35M Series D (Oct 2025, J.P. Morgan Life Sciences Private Capital lead). The Route90 pivotal trial completed enrollment of 120 patients across 20 international sites in February 2026, setting up a near-term PMA submission. The strategic posture is that of a late-clinical-stage device company transitioning toward U.S. commercialization with secured isotope supply and dedicated manufacturing capacity.
ABK Biomedical firmographics
Firmographics- Name
- ABK Biomedical
- Legal name
- ABK Biomedical Inc.
- Website
- https://abkbiomedical.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ABK Biomedical is a clinical-stage medical device company developing proprietary glass-based Y-90 radioembolization microspheres (Eye90) and embolic microspheres (Easi-Vue) for interventional oncology treatment of liver cancer patients.
- Ownership category
- akta.pro rank
ABK Biomedical industry classification
Industry- Product category
- Interventional Oncology Medical Devices
- NAICS
- Irradiation Apparatus Manufacturing (334517), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH), Radiation Oncology (HLAKAFAC)
Keywords
Where ABK Biomedical is headquartered
LocationHeadquarters
- HQ city
- Halifax
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
ABK Biomedical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Eye90 microspheres (pre-commercial): ABK Biomedical is a clinical-stage company developing Eye90 microspheres for Y90 radioembolization of liver tumors. The product is not yet FDA-approved and is currently only available through clinical trials. Revenue will be generated upon FDA approval and commercialization, likely through direct hospital/health system sales.
- Easi-Vue embolic microspheres (FDA 510(k) cleared): Easi-Vue has received FDA 510(k) clearance for embolization of arteriovenous malformations and hypervascular tumors, representing the company's only commercially available product as of the data period.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ABK Biomedical product offering
Product offeringCore offering
ABK Biomedical develops and manufactures imageable embolic microsphere technologies for interventional oncology. Its portfolio includes Eye90 microspheres, an investigational Yttrium-90 radioembolization product designed for liver cancer treatment with CT-visualizable precision dosimetry, and Easi-Vue embolic microspheres, an FDA 510(k) cleared bland embolization device. The proprietary radiopaque glass composition allows clinicians to directly visualize embolic distribution under CT, fluoroscopy, and ultrasound imaging.
Product overview
ABK Biomedical is a clinical-stage medical device company developing a portfolio of imageable embolic microsphere technologies for interventional oncology. The product portfolio consists of two distinct products: Eye90 microspheres® (an investigational Y90 radioembolization device for liver cancer treatment currently undergoing FDA IDE pivotal trials) and Easi-Vue™ embolic microspheres (an FDA 510(k)-cleared imageable bland embolization product). Both products leverage proprietary radiopaque glass composition technology enabling physician visualization during procedures via CT imaging. The company is headquartered in Halifax, Nova Scotia, with operations in Ladera Ranch, California.
Differentiator
Problem solved
Functional benefit
Brands
- Eye90 microspheres®: A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization. FDA-designated breakthrough technology for liver cancer treatment.
- Easi-Vue™ embolic microspheres
Products and services
- Eye90 Microspheres Investigational Yttrium-90 radioembolization microspheres designed for liver cancer treatment, featuring proprietary radiopaque glass composition that enables CT-based precision dosimetry and direct visualization of microsphere distribution. The dual-syringe administration system allows smaller-diameter delivery for deeper tumor penetration. Indicated for interventional oncology procedures treating hepatocellular carcinoma and metastatic liver cancer.
- Easi-Vue Embolic Microspheres FDA 510(k) cleared bland embolization microspheres indicated for transarterial embolization procedures. The proprietary radiopaque glass composition enables multi-modality imaging visibility under CT, fluoroscopy, and ultrasound, allowing clinicians to directly visualize embolic distribution following deployment. Used by interventional radiologists and interventional oncologists for embolization of hypervascular tumors.
Quantifiable outcome
- 120 patients enrolled across 20 international sites in Route90 pivotal Phase III FDA IDE study (largest prospective FDA IDE trial for Y90 radioembolization of HCC)
- +2 more outcomes
Companies that use ABK Biomedical
Customer profileSegments1 record
Ideal customer profiles1 record
ABK Biomedical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ABK Biomedical partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Missouri University Research Reactor (MURR)coreLong-term partnership agreement naming MURR as the primary irradiation partner for Eye90 microspheres. MURR is currently the only location in the United States producing Y-90 for clinical and commercial use. The partnership formalizes seven years of collaboration and secures a reliable, scalable production partner as ABK transitions toward commercialization.
- COR DevelopmentcoreStrategic partnership to develop a state-of-the-art GMP manufacturing facility in Ashland, Missouri (Cartwright Business Park) dedicated to commercial-scale production of Eye90 microspheres. COR Development is developing the facility infrastructure. This represents a core partnership for long-term commercial manufacturing capacity.
- Coil ConstructionminorConstruction firm overseeing the design and construction of the GMP manufacturing facility in Ashland, Missouri at Cartwright Business Park.
- University of Missouri College of Veterinary MedicineminorPartnership for First-in-Dog (FIDO) HCC study evaluating Eye90 microspheres treatment in canine patients with hepatocellular carcinoma, generating preclinical/clinical evidence for the technology.
- Dalhousie UniversityminorFounding institution and research partner. ABK Biomedical was founded at Dalhousie University in 2012 and maintains ongoing research collaboration.
- MD Anderson Cancer CenterminorResearch partner collaborating on clinical studies and data analysis for Eye90 microspheres technology.
- North Carolina State UniversityminorResearch partner that collaborated with ABK to develop a novel hepatic tumor microvascular model for evaluating Y90 microsphere deposition characteristics.
- Northwestern UniversityminorAcademic research partner involved in scientific research and clinical studies for Eye90 microspheres.
- Syneos HealthminorClinical research organization partner providing clinical development expertise.
- Sarah Cannon Research Institute (SCRI)minorCo-principal investigators from HCA Healthcare Sarah Cannon Cancer Network lead the Route90 pivotal trial, contributing to clinical study design and execution.
- ProPharmaminorResearch partner providing regulatory and compliance consulting services.
- Paragon MedicalminorDevelopment partner contributing to product development and manufacturing processes.
- SandfireminorDevelopment partner contributing to product development.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
ABK Biomedical competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare is a dominant imaging equipment vendor (CT, fluoroscopy, PET/CT) used with Eye90 for both delivery visualization and dosimetry. While not a direct microsphere competitor, it is a critical ecosystem participant and adjacent incumbent.
- Varian (a Siemens Healthineers company): Varian is a radiation oncology incumbent (and prior ABK investor) offering a broad portfolio spanning external beam radiotherapy, proton therapy, and software. They have historically commercialized SIR-Spheres via their acquisition of BTG/Biocompatibles, making them a channel-relevant incumbent.
- Boston Scientific (TheraSphere): Boston Scientific owns TheraSphere, the only other Y-90 glass microsphere product on the market. ABK's imageable Eye90 is differentiated structurally from TheraSphere, but they compete head-to-head for the same physician customers and HCC/mCRC indications.
Emerging players
- AngioDynamics: AngioDynamics develops NanoKnife and other interventional oncology and embolization products. Smaller than the Y90 microsphere incumbents but a relevant peer in the interventional oncology and locoregional treatment space that competes for the same HCC patient population.
- Terumo (QuiremSpheres): Terumo distributes QuiremSpheres (holmium-166 microspheres) in Europe, a directly analogous radioembolization product targeting similar liver tumor indications. Different isotope, same procedural channel and call point, positioning it as an emerging alternative.
Direct peers
- Guerbet: Guerbet supplies Lipiodol and other interventional imaging and locoregional oncology products, competing in interventional radiology procedures for HCC. Same end users and same procedural workflow competition.
- Cook Medical: Cook Medical offers a broad embolization product portfolio used by interventional radiologists, including microsphere and occlusion products that overlap with ABK's Easi-Vue. Direct overlap in interventional oncology procurement decisions.
- Merit Medical Systems: Merit Medical markets a portfolio of embolization, tumor ablation, and interventional oncology devices. Comparable procedural call points and indications (liver embolization), and a likely competitive overlap with both Eye90 and Easi-Vue.
- Sirtex Medical: Sirtex markets SIR-Spheres Y-90 resin microspheres, the principal direct competitor to ABK's Eye90 in Y90 radioembolization for liver tumors. Comparable patient indication, delivery modality, and purchaser base (interventional oncology).
- Penumbra: Penumbra is a leading interventional device company developing embolization, thrombectomy, and interventional oncology products. Comparable customer base (interventional radiologists) and adjacent product categories in imageable/targeted embolization.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ABK Biomedical social profiles
Digital presenceABK Biomedical compliance and trust
Trust signalCompliance1 record
ABK Biomedical financial estimates
Financial estimateRevenue estimate
Valuation estimate
ABK Biomedical leadership team
Management profileNumber of profiles
Profiles5 records
ABK Biomedical funding detail
Funding detailFunding overview
Funding rounds7 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ABK Biomedical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ABK Biomedical
What does ABK Biomedical do?
ABK Biomedical develops and manufactures imageable embolic microsphere technologies for interventional oncology. Its portfolio includes Eye90 microspheres, an investigational Yttrium-90 radioembolization product designed for liver cancer treatment with CT-visualizable precision dosimetry, and Easi-Vue embolic microspheres, an FDA 510(k) cleared bland embolization device. The proprietary radiopaque glass composition allows clinicians to directly visualize embolic distribution under CT, fluoroscopy, and ultrasound imaging.
When was ABK Biomedical founded?
ABK Biomedical was founded in 2012. It employs 11 to 50 people.
Where is ABK Biomedical based?
ABK Biomedical is headquartered in Halifax, Canada, in the North America region.
How does ABK Biomedical make money?
Two revenue lines are on record. Eye90 microspheres (pre-commercial) is the primary driver. The others are easi-Vue embolic microspheres (FDA 510(k) cleared).
Who are ABK Biomedical's main competitors?
Broad incumbents on record are GE HealthCare, Varian (a Siemens Healthineers company) and Boston Scientific (TheraSphere). Emerging players are AngioDynamics and Terumo (QuiremSpheres). Direct peers are Guerbet, Cook Medical, Merit Medical Systems, Sirtex Medical and Penumbra.
Does ABK Biomedical have an API?
No public API is recorded for ABK Biomedical.
What industry is ABK Biomedical in?
ABK Biomedical's product category is Interventional Oncology Medical Devices. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAHADAH, Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence). Its NAICS code is 334517 and its SIC code is 3841.